Chemotherapy Induced Peripheral Neuropathy - Drug Pipeline Landscape, 2023
Description
Chemotherapy Induced Peripheral Neuropathy - Drug Pipeline Landscape, 2023
Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment that can cause tingling, numbness, and pain in the hands and feet. CIPN is caused by damage to the nerves that send signals from the body to the brain.
Chemotherapy-induced neuropathy is caused by a substantial number of cytotoxic drugs, including taxanes, platinums, vinca alkaloids, epothilones, eribulin, and bortezomib; these drugs cause different pathologic insults to neurons.
The symptoms of CIPN can range from mild to severe, and they can last for weeks, months, or even years after treatment has ended. There is no cure for CIPN, but there are treatments that can help lessen the symptoms.
There are many companies actively developing chemotherapy induced peripheral neuropathy drugs, including Eisai Co Ltd, Asahi Kasei Pharma Corp, and Advinus Therapeutics Ltd.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Chemotherapy Induced Peripharal Neurophaty treatment such as Nicotinamide Riboside, PSP Neuro Serum, Venlafaxine and others. Key players involved in the development of therapies to treat Chemotherapy Induced Peripharal Neurophaty are Bexion Pharmaceuticals Inc, Eisai Co Ltd, MediciNova, Mendel AI, Novaremed and others. One drug is under late-stage Phase III clinical trials and six drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.
Report Highlights
Global Insight Service's, Chemotherapy Induced Peripheral Neuropathy - Drug Pipeline Landscape, 2023 report provides an overview of the Chemotherapy Induced Peripheral Neuropathy pipeline drugs. This report covers detailed insights on Chemotherapy Induced Peripheral Neuropathy drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Chemotherapy Induced Peripheral Neuropathy pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment that can cause tingling, numbness, and pain in the hands and feet. CIPN is caused by damage to the nerves that send signals from the body to the brain.
Chemotherapy-induced neuropathy is caused by a substantial number of cytotoxic drugs, including taxanes, platinums, vinca alkaloids, epothilones, eribulin, and bortezomib; these drugs cause different pathologic insults to neurons.
The symptoms of CIPN can range from mild to severe, and they can last for weeks, months, or even years after treatment has ended. There is no cure for CIPN, but there are treatments that can help lessen the symptoms.
There are many companies actively developing chemotherapy induced peripheral neuropathy drugs, including Eisai Co Ltd, Asahi Kasei Pharma Corp, and Advinus Therapeutics Ltd.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Chemotherapy Induced Peripharal Neurophaty treatment such as Nicotinamide Riboside, PSP Neuro Serum, Venlafaxine and others. Key players involved in the development of therapies to treat Chemotherapy Induced Peripharal Neurophaty are Bexion Pharmaceuticals Inc, Eisai Co Ltd, MediciNova, Mendel AI, Novaremed and others. One drug is under late-stage Phase III clinical trials and six drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.
Report Highlights
Global Insight Service's, Chemotherapy Induced Peripheral Neuropathy - Drug Pipeline Landscape, 2023 report provides an overview of the Chemotherapy Induced Peripheral Neuropathy pipeline drugs. This report covers detailed insights on Chemotherapy Induced Peripheral Neuropathy drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Chemotherapy Induced Peripheral Neuropathy pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
102 Pages
- 1. Introduction
- 1.1 Chemotherapy Induced Peripheral Neuropathy - Pipeline Drugs, 2023 - Coverage
- 2. Disease Overview - Chemotherapy Induced Peripheral Neuropathy
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Chemotherapy Induced Peripheral Neuropathy - Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Clinical Stage Drugs-Phase III
- 5.1.1 Venlafaxine
- 5.2 Clinical Stage Drugs-Phase II
- 5.2.1 Ibudilast
- 5.2.2 MP-101
- 5.2.3 Nicotinamide Riboside
- 5.2.4 PSP NEURO SERUM
- 5.2.5 SON-080
- 5.2.6 Tetrodotoxin
- 5.3 Clinical Stage Drugs-Phase I
- 5.3.1 EA4017
- 5.3.2 Ricolinostat
- 5.3.3 thrombomodulin alfa
- 5.3.4 WST-057
- 5.4 Clinical Stage Drugs-Phase 0
- 5.4.1 BXQ-350
- 5.5 Early Stage Drugs-Preclinical
- 5.5.1 AJ302
- 5.5.2 AM 1710
- 5.5.3 EQ-6
- 5.5.4 FAAH inhibitors
- 5.5.5 KLS-13019
- 5.5.6 NB-01
- 5.5.7 OSM-0205
- 5.5.8 PGN-503
- 5.5.9 SP-04
- 5.6 Early Stage Drugs-Discovery
- 5.6.1 Drug for CIPN
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 Advinus Therapeutics Ltd
- 9.2 Algenis SpA
- 9.3 AnnJi Pharmaceutical
- 9.4 Asahi Kasei Pharma Corp
- 9.5 AxoProtego Therapeutics
- 9.6 Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.
- 9.7 Bexion Pharmaceuticals, Inc
- 9.8 ChromaDex, Inc
- 9.9 Eisai Co Ltd
- 9.10 Enveric Biosciences
- 9.11 KannaLife Sciences
- 9.12 MakScientific
- 9.13 MediciNova
- 9.14 Mendel AI
- 9.15 NeuroBo Pharmaceuticals
- 9.16 Novaremed
- 9.17 Osmol Therapeutics
- 9.18 PeriphaGen
- 9.19 Solasia Pharma
- 9.20 Sonnet BioTherapeutics
- 9.21 Wex Pharmaceuticals Inc.
- 9.22 Winsantor
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11. Appendix
- List of Tables
- Table 1.1 Number of Products under Development by Chemotherapy Induced Peripheral Neuropathy
- Table 1.2 Number of Products under Development by Companies
- Table 1.3 Products under Development by Companies
- Table 1.4 Products by Targets
- Table 1.5 Products by Mechanism of Action
- Table 1.6 Products by Molecule Type
- Table 1.7 Products by Route of Administration
- Table 2.1 Clinical Trial Details - Venlafaxine/Mendel AI
- Table 2.2 Clinical Trial Details - Nicotinamide Riboside/ChromaDex, Inc.
- Table 2.3 Clinical Trial Details - PSP NEURO SERUM/Algenis SpA
- Table 2.4 Clinical Trial Details - SON-080/Sonnet BioTherapeutics, Inc
- Table 2.5 Clinical Trial Details - Tetrodotoxin/Wex Pharmaceuticals Inc..
- Table 2.6 Clinical Trial Details - EA4017/Eisai Co Ltd
- Table 2.7 Clinical Trial Details - Ricolinostat/Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.
- Table 2.8 Clinical Trial Details - Thrombomodulin alfa/Asahi Kasei Pharma Corp
- Table 2.9 Clinical Trial Details - WST-057/Winsantor
- Table 2.10 Clinical Trial Details - BXQ-350/Bexion Pharmaceuticals, Inc
- Table 3.1 Regulatory Designations
- Table 4.1 Inactive Drugs
- Table 4.2 Discontinued Drugs
- List of Figures
- Figure 1.1 Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, 2023
- Figure 1.2 Products by Top 5 Targets and Stage of Development for Chemotherapy Induced Peripheral Neuropathy, 2023
- Figure 1.3 Products by Top 5 Mechanism of Action and Stage of Development for Chemotherapy Induced Peripheral Neuropathy, 2023
- Figure 1.4 Products by Top 5 Molecule Type and Stage of Development for Chemotherapy Induced Peripheral Neuropathy, 2023
- Figure 1.5 Products by Top 5 Route of Administration and Stage of Development for Chemotherapy Induced Peripheral Neuropathy, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
